Ending $10 billion in payments for cost-sharing assistance would lead to the U.S. to pay out more $12 billion in other subsidies. » Read More
Eli Lilly reported a bigger-than-expected profit as the drugmaker benefited from higher demand for its newer products including diabetes treatment Trulicity. » Read More
By: Michelle Fox
The fact that Anthem wants to cut ties with Express Scripts is "perplexing," Express Scripts CEO Tim Wentworth told CNBC on Monday. » Read More
Any vote on healthcare legislation would be determined by Republican leaders when they have enough votes, White House spokesman Sean Spicer said. » Read More
Sanofi on Monday sued Mylan, accusing the pharmaceutical company of engaging in illegal conduct to squelch competition to its EpiPen allergy treatment
This Saturday's March for Science is trying hard to be a nonpartisan event, but some may not see it that way.
The new plan to repeal and replace Obamacare is an attempt to bridge the gap between the House Freedom Caucus and moderates.
Increases in the prices of drugs added $8.7 billion to 2016 net income for 28 companies analyzed, accounting for 100 percent of earnings growth last year.
The memo is a mid-April summation of the changes Republicans are negotiating for the new health-care bill.
The new GOP health bill is just Obamacare with "limited waivers," says Jake Novak.
An analysis commissioned by pharmacy benefits managers revealed no correlation between drug prices and rebates.
The notorious pharma bro Shkreli denies claims he looted a drug company he founded to pay off hedge fund investors he allegedly defrauded.
Intuitive Surgical said it shipped 133 of its da Vinci surgical systems in the first quarter of 2017.
UnitedHealth is confident it will post better-than-expected growth for the full year, regardless of what happens with health reform.
In the last week, New Hampshire, Kentucky and Colorado have moved rate deadlines to June from April or May.
Cardinal Health says it expects earnings at the lower end of its forecast, causing a 12 percent tumble in shares.
The largest U.S. health insurer reported a 9.4 percent rise in quarterly revenue, driven by strength in its pharmacy benefit management business.
America’s most interesting policy fight is between the Republicans’ real and fake health policies, says Ezra Klein.
The news weighed on stocks in the hospital sector Monday, overshadowing some positive regulatory changes from the Trump administration.
Lilly says the FDA needed additional data to "characterize safety concerns across treatment arms."
Get the best of CNBC in your inbox